Precision Oncology 2025 in Review: New Targets, Liquid Biopsy, and AI-Driven Insights
This annual review summarizes key advances in precision oncology during 2025, including new indications for known targeted agents, early data on previously undruggable targets, continued development of antibody-drug conjugates and PROTACs, and multiple blood-based early cancer detection methodologies. The authors highlight the identification of non-traditional precision biomarkers and the growing role of AI technologies in generating actionable oncology insights. The review provides a useful landscape overview for diagnostics professionals tracking companion diagnostic and liquid biopsy developments.
The original study
Precision Oncology: 2025 in Review.
- Authors
- Mai N, Fernandez N, Drilon A, Chakravarty D
- Journal
- Cancer discovery
- Type
- Journal Article, Review
- PMID
- 41327967
Original abstract
This article discusses the specific advances made in precision oncology in 2025, in which we saw the approval of multiple new indications for known precision oncology agents and early promising data for novel agents that target either classical pathways or previously so-called undruggable targets. Additionally, we observed the continued development of antibody-drug conjugates and proteolysis-targeting chimeras, the advent of multiple blood-based methodologies for the early detection of cancer, the identification of nontraditional precision oncology biomarkers, and the growing presence of artificial intelligence technologies to generate precision oncology insights.